Biodextris Invests in New Biologics Contract Development, Manufacturing Center

Biodextris Inc., a subsidiary of Clean Biologics SAS, announced the development of a new industrial-scale vaccine and biologics development, manufacturing and packaging plant.

The new facility will support companies in the development and characterization of next-generation biological products and will help bridge the gap between research projects and large-scale commercial production.

The center will begin operations in the summer of 2023, and the company expects to add about 15 specialized staff members to its team over the next few years.

Biodextris is investing $25 million in indoor layout and state-of-the-art materials and equipment.

Located in Laval’s Biotech City, the 30,000 sq.-ft. building will be custom developed to meet Biodextris’ needs.

Overall, the center will include three main spaces: laboratory space dedicated to bioprocess development, analytical laboratories for development, method validation and quality control of manufactured products and finally, five dedicated cGMP biomanufacturing suites.

The production service offer will be enhanced by the addition of larger volume bioreactors (50 to 200 liters) and by the addition of an aseptic filling capacity.

The project has received support from the governments of Quebec and Canada and from Investissement Québec.

In addition, the Quebec government granted a $4 million loan under the ESSOR program, managed by Investissement Québec.

Investissement Québec also granted a $1.4 million loan through its own funds. For its part, the Government of Canada is supporting the project with a repayable contribution of $1 million, granted under the Regional Economic Growth through Innovation program of Canada Economic Development for Quebec Regions (CED).

CED’s assistance will be used to purchase and install biology, biophysics, and medical chemistry equipment. The equipment will enable the SME to become more competitive and continue to grow.

The new biomanufacturing center (cGMP) and its analytical capabilities are expected to be an asset in the development of Biodextris as a world-class CDMO.

“Our company’s biologics development scientist team will be able to support our customers and offer them a range of integrated services and the most advanced technologies, from the initial development phases, through clinical trials, to commercial manufacturing of the product,” said Alain Carrier, general manager of Biodextris.